State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens
Seminars in Respiratory and Critical Care Medicine · 01.02.2025 · 46 (01) · 063-081
DOI: 10.1055/a-2500-1878 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.02.2025. Verfasst von Matteo Ridelfi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Vaccine Development, Bacterial Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 227 Literaturangaben.
Abstract (Originalsprache)
In this review, we present the efforts made so far in developing effective solutions to prevent infections caused by seven major respiratory pathogens: influenza virus, respiratory syncytial virus (RSV), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Bordetella pertussis, Streptococcus pneumoniae (pneumococcus), Mycobacterium tuberculosis, and Pseudomonas aeruginosa. Advancements driven by the recent coronavirus disease 2019 (COVID-19) crisis have largely focused on viruses, but effective prophylactic solutions for bacterial pathogens are also needed, especially in light of the antimicrobial resistance (AMR) phenomenon. Here, we discuss various innovative key technologies that can help address this critical need, such as (a) the development of Lung-on-Chip ex vivo models to gain a better understanding of the pathogenesis process and the host–microbe interactions; (b) a more thorough investigation of the mechanisms behind mucosal immunity as the first line of defense against pathogens; (c) the identification of correlates of protection (CoPs) which, in conjunction with the Reverse Vaccinology 2.0 approach, can push a more rational and targeted design of vaccines. By focusing on these critical areas, we expect substantial progress in the development of new vaccines against respiratory bacterial pathogens, thereby enhancing global health protection in the framework of the increasingly concerning AMR emergence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
- Fondazione Biotecnopolo di Siena, Siena, Italy.
Zitieren
APA
Ridelfi, M., Pierleoni, G., Zucconi Galli Fonseca, V., Batani, G., Rappuoli, R., & Sala, C. (2025). State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens. Seminars in Respiratory and Critical Care Medicine, 46(01), 063-081. https://doi.org/10.1055/a-2500-1878
Vancouver
Ridelfi M, Pierleoni G, Zucconi Galli Fonseca V, Batani G, Rappuoli R, Sala C. State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens. Seminars in Respiratory and Critical Care Medicine. 2025;46(01):063-081. doi:10.1055/a-2500-1878
BibTeX
@article{Ridelfi2025,
author = {Ridelfi, Matteo and Pierleoni, Giulio and Zucconi Galli Fonseca, Vittoria and Batani, Giampiero and Rappuoli, Rino and Sala, Claudia},
title = {State of the Art and Emerging Technologies in Vaccine Design for Respiratory Pathogens},
journal = {Seminars in Respiratory and Critical Care Medicine},
year = {2025},
volume = {46},
number = {01},
pages = {063--081},
doi = {10.1055/a-2500-1878}
}
EUVIMED